I
nflammatory bowel disease (IBD) is a complex, multifactorial, lifelong disease of the gastrointestinal (GI) tract that is divided into 2 predominant phenotypes: Crohn's disease and ulcerative colitis. IBD is characterized by chronic inflammation of the GI tract and causes symptoms such as abdominal pain, bloody diarrhea, and weight loss, as well as symptoms specific to pediatriconset IBD including growth failure, impaired bone mineralization, and pubertal delay. With an estimated annual disease-attributable direct cost in the United States in excess of $6.3 billion 1 and an estimated 1.6 million affected people in the United States, 2 IBD is one of the most prevalent and costly GI disorders whose annual incidence and prevalence is on the rise. IBD places a significant burden on affected individuals because of the detrimental effects on quality of life, growth and development, and risk of malignancy later in life. 3 The cause of IBD and its flare-ups is thought to involve dysregulation of the immune response, and the conventional treatment includes immunosuppression to induce and maintain remission. Current immunosuppressive therapies available for the treatment of IBD offer limited benefits, lose effectiveness rapidly, and carry multiple long-term risks including malignancy, infection, and low bone density. 4 These faults of the available therapies as well as their known complications expose a significant need for the development of highly novel therapies for the treatment of IBD.
One pathway that may offer a novel approach to enhance the impaired host regulatory system in patients with IBD is the endogenous cannabinoid (endocannabinoid) pathway. Although cannabinoids are traditionally characterized as being synonymous with plant-derived Cannabis or marijuana (MJ), there is an innate, mammalian endocannabinoid system (ECS) that includes endogenous ligands termed endocannabinoids, their cannabinoid receptors, and the proteins involved in endocannabinoid biosynthesis and degradation. Several physiological effects and pathophysiological roles have been proposed for the ECS in the GI tract, including effects on epithelial growth and regeneration, immune function, motor function, appetite control, and secretion. 5 Anecdotal and limited scientific evidence suggests that MJ use may have a positive impact on patients with IBD because of its analgesic and antiinflammatory effects. 6 Cannabinomimetics can provide patients with IBD symptomatic relief by improving appetite, stimulating weight gain, reducing abdominal pain, and decreasing intestinal motility, but their anti-inflammatory function remains unclear. 7 Because of legalization of medical MJ and its increased use in the setting of inflammatory diseases, this uncertainty has sparked a focus on basic science research to further elucidate the biological effects of manipulation of the ECS. In this review, we will focus on defining the ECS, and highlight the current data from targeting of the cannabinoid receptors 1 and 2, endogenous cannabinoids, atypical cannabinoids, and the enzymes of degradation in murine colitis.
THE ECS
The ECS comprises endogenous ligands termed endocannabinoids, their cannabinoid receptors, and the proteins involved in endocannabinoid biosynthesis and degradation. The primary endocannabinoids are arachidonoyl ethanolamines, also known as anandamide (AEA), and 2-arachidonoylglycerol (2-AG). These endogenous ligands are lipid mediators that, in contrast to classic neurotransmitters which are stored in vesicles, are synthesized ondemand from membrane precursors and phospholipids 8 including N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD), then released from cells immediately after production. 5 They activate receptors to elicit a biological response, then become inactivated through reuptake by carrier proteins in the cell membrane named the endocannabinoid membrane transporters, followed by enzymatic degradation. AEA is degraded by fatty acid amide hydrolase (FAAH) in to arachidonic acid and ethanolamine and 2-AG is degraded by monoacylglycerol lipase (MAGL) in to arachidonic acid and glycerol. 5 The endocannabinoids AEA and 2-AG act primarily on 2 heterotrimeric G protein-coupled receptors, the cannabinoid 1 (CB 1 ) receptor and cannabinoid 2 (CB 2 ) receptor. CB 1 receptors are located primarily on central and peripheral neurons, and more specifically in the enteric nervous system, intrinsic neurons, extrinsic neurons such as the cell bodies of sensory neurons in the dorsal root ganglia and nodose ganglion, and vagal efferent nerves, as well as on epithelial cells. 8 In neurons, endocannabinoids act mainly presynaptically, modulating the transmission of other neurotransmitters including g-aminobutyric acid, glutamate, and acetylcholine. 8 CB 2 receptors are mainly expressed on immune cells, specifically, neutrophils, activated macrophages, and subsets of T and B cells, as well as on epithelial cells. 9 CB 1 receptors modulate neurotransmitter release, whereas CB 2 receptors are mainly associated with immune functions. 5 In addition to signaling through CB 1 and CB 2 receptors, endocannabinoids also activate the transient receptor potential vanilloid type 1 (TRPV1), which is mainly expressed by primary afferent neurons, as well as the orphan G protein-coupled receptor GPR55 5 (Fig. 1) .
Other endogenous molecules exhibit "cannabinoid-like" effects and may be termed atypical endocannabinoids, including 2-arachidonoylglycerol ether (noladin ether), N-arachidonoyl dopamine (NADA), virodhamine, N-homo-g-linolenoyl-ethanolamine (HEA) and N-docosatetraenoyl-ethanolamine (DEA), palmitoylethanolamide (PEA), and oleoylethanolamide. These additional molecules do not seem to bind to cannabinoid receptors but rather to non-CB 1 or CB 2 receptors or to a specific isozyme belonging to a class of nuclear receptors/transcription factors with 3 subsets, known as the alpha, beta (delta), or gamma peroxisome proliferator-activated receptors (PPARs). However, these atypical endocannabinoids may augment the effect of AEA by competitive inhibition of FAAH, or through allosteric effects on other receptors such as ion channel TRPV1, and thus play an important, although less defined role in the ECS. 10 Cannabinoid 1 Receptor CB 1 receptor expression is significantly increased in models of inflammation, with increased expression demonstrated by Western blot analysis in croton oil-induced inflammation of the jejunum, 11 by increased mRNA expression in dinitrobenzene sulfonic acid (DNBS)-induced colitis, 12 dextran sulfate sodium (DSS)-induced murine colitis, 13 and in lipopolysaccharide (LPS)-stimulated peritoneal macrophages, 14 and was shown by immunostaining of colonic sections to be increased in myenteric ganglia in both oil of mustard (OM) and DSS-induced colitis, as well as in the endothelium of OM-induced colitis. 15 In addition, mRNA expression of CB 1 receptor is upregulated in both DNBS-induced colitis and control mice when treated with the atypical cannabinoid PEA. 16 Based on this link of upregulated expression of the CB 1 receptor in inflammation, many studies have sought to demonstrate the key role of the CB 1 receptor in attenuation of murine colitis. CB 1 receptor agonist ACEA attenuated inflammation in OM and DSS-induced colitis models. 15 Massa et al 12 showed that treatment with CB 1 receptor agonist R(-)-7-hydroxy-Δ6-tetra-hydrocannabinol-dimethylheptyl (HU210) in DNBS-induced colitis consistently resulted in protection against colitis. Furthermore, WIN55, 212-2, a weakly selective CB 1 receptor agonist, protects against TNBSinduced colitis 17 in one particular study; however, this model does not reflect the inflammatory cascade found in human disease. WIN 55, 212-2 was also found to be protective against DSS-induced colitis in wild-type (WT) mice, 17, 18 and this protective effect is further enhanced in C57BL Mk2 2/2 mice, demonstrating an amplified benefit with simultaneous activation of the CB 1 pathway while blocking p38/Mk2 proinflammatory pathway. 18 Genetically engineered knockout mouse models have been instrumental in elucidating the CB 1 receptor pathways of the ECS. Both 2,4,6-trinitrobenzene sulfonic acid (TNBS) and DSS treatment induced more severe colitis in CB 1 2/2 mice than in WT littermates, and treatment with the specific CB 1 antagonist N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A) mimicked the phenotype of CB 1 2/2 mice, showing an acute requirement of CB 1 receptors for protection from inflammation. 12 Engel et al 19 reaffirmed this finding several years later by showing that TNBSinduced colitis in CB 1 2/2 mice had a higher stool score, increased colon weight, a shorter colon, higher macroscopic and histologic scores, and increased mRNA expression of IL-1b and TNF-a, indicating a more severe colitis in the absence of the CB 1 receptor. Many compounds act through the ECS in a broader sense and only recently have the pathways through CB 1 receptor been more clearly explained. One such study demonstrated that oral treatment with a,b-amyrin, a pentacyclic triterpene, reduced leukocyte infiltration and proinflammatory cytokine production, and reduced inhibition of adhesion molecule expression. 13 These changes indicated that a,b-amyrin attenuated DSS-induced colitis, and this protective and therapeutic effect was partially reversed with the use of CB 1 receptor antagonist AM251, whereas CB 2 antagonist aminoalkylindole 6-iodo-pravadoline (AM630) failed to reduce the anti-inflammatory benefit of a, b-amyrin. 13 In addition, the enzymatic degradation pathway of the compound PF-3845, a potent and selective FAAH inhibitor, is mediated by the CB 1 receptor pathway, as administration of CB 1 receptor antagonist AM251 blocked the anti-inflammatory effect of PF-3845 in TNBS-induced colitis, whereas CB 2 blockade with CB 2 selective antagonist AM630 had no effect on inflammation. 20 Overall, although these described studies provided no strong consensus of the mechanism of CB 1 -mediated attenuation of intestinal inflammation, in vitro studies describing a CB 1 -selective improvement in intestinal epithelial barrier restitution after inflammatory insult suggest that this may represent one mechanism through which CB 1 receptors are protective. 21 
Cannabinoid 2 Receptor
Mirroring the upregulation of CB 1 receptors in inflammation, CB 2 receptor mRNA expression is increased in chemically induced colitis, 22 and CB 2 receptors are highly expressed on infiltrated immune cells in colonic sections in OM-induced colitis and to a lesser extent, in DSS-colitis as demonstrated by immunostaining. 15 However, in vitro LPS stimulation of peritoneal macrophages led to decreased mRNA expression of CB 2 receptors in one study. 14 Furthermore, CB 2 receptors have also been shown to play a critical role in the attenuation of murine colitis. Both plantderived D9-tetrahydrocannabinol (THC) and endogenous cannabinoid AEA demonstrated an anti-inflammatory effect in in vitro cell assays of antibody formation, and these effects were blocked by CB 2 receptor antagonist SR144528 but not by CB 1 receptor antagonist SR141716. 23 Moreover, CB 2 agonist JWH-133 has been shown to inhibit LPS/interferon (IFN)-g-induced proinflammatory cytokine IL-12p40 in vitro 24 and induce apoptosis in activated T cells both in vivo and in vitro. 25 In addition, CB 2 activation with JWH-133 also ameliorates inflammation in IL-10 2/2 colitic mice, 25 as well as in chemically induced colitis. 15, 25 These protective effects of JWH-133 in DSS-colitis were reversed in the presence of CB 2 receptor antagonist AM630. 25 Similar findings were demonstrated in TNBS-induced colitis; CB 2 agonists JWH-133 and AM1241 significantly reduced murine colitis, and CB antagonist AM630 exacerbated colitis and abolished the anti-inflammatory effect of JWH-133 when given as a pretreatment in the colitis model. 22 Genetically engineered CB 2 receptor knockout mice further confirmed the importance of the CB 2 pathway in attenuation of murine colitis. In the previously described study, neither JWH-133 nor AM1241 maintained their antiinflammatory effects on TNBS-induced colitis in CB 2 2/2 mice. 22 Engel et al's 2010 study reiterated the importance of the CB 2 receptor pathway by showing that TNBS-induced colitis in CB 2 2/2 mice had increased mRNA expression of IL-1b and TNF-a and a more severe colitis in the absence of the CB 2 receptor. 19 The CB 2 receptor pathway also modulates the effects of several atypical cannabinoids. In the DNBS-induced colitis model, the beneficial effects of treatment with atypical cannabinoid PEA were abolished by CB 2 antagonist AM630 (as well as by GPR55 and PPAR antagonists), but the CB 1 antagonist rimonabant did not have any effect. 16 The CB 2 receptor pathway was also found to modulate the favorable effects of cannabigerol (CBG), a nonpsychotropic cannabinoid capable of reducing nitric oxide production in macrophages and attenuating murine DNBS-induced colitis in both a preventive (pretreatment) model and therapeutic (established colitis) model. 26 In these models, treatment with CB 2 antagonist SR144528 further increased the inhibitory effect of CBG on nitric oxide production. 26 Finally, the plant metabolite b-caryophyllene (BCP) ameliorates DSSinduced and oxazolone-induced colitis in a dose-dependent manner, and this effect was reversed in the presence of CB 2 antagonist AM630 and in the presence of PPAR antagonist GW9662, suggesting that the anti-inflammatory effect of BCP not only involves CB 2 receptor pathway, but also the PPAR pathway. 27 Based on evidence that CB 2 receptor agonism demonstrates promising therapeutic benefits in murine colitis, several novel, highly selective CB 2 receptor agonists were developed, of which 2 of these compounds had promising in vivo anti-inflammatory effects in the DSS-induced colitis model. 28 Furthermore, El Bakali et al developed constrained analogs from 4-oxo-1,4-dihydroquinoline-3-carboxamides with improved affinity for the CB 2 receptor and increased selectivity over the CB 1 receptor and tested their effects on prevention and treatment of TNBS-induced colitis; the highly CB 2 receptor selective agonistic compound 26 (ALICB459) exerted a strong protective effect when given orally to mice with TNBSinduced colitis 29 (Table 1) .
Endogenous Cannabinoids
Endogenous cannabinoids AEA and 2-AG signal through cannabinoid receptors and are also fundamental in the pathway to attenuate murine colitis. AEA is upregulated in LPS-stimulated peritoneal macrophages, 14 and levels of endogenous cannabinoids AEA and 2-AG are elevated through investigation by isotope dilution liquid chromatography-mass spectrometry in DNBS-induced colitis, whereas treatment with plant-derived, anti-inflammatory cannabinoid cannabidiol (CBD) significantly counteracted these changes. 30 In addition, intraperitoneal administration of AEA ameliorates macroscopic and microscopic colonic inflammation and suppresses the expression of proinflammatory cytokines in AKR mice with TNBS-induced colitis. 31 Furthermore, selective MAGL inhibitor JZL184 prevents degradation of 2-AG and thus allows 2-AG to activate cannabinoid receptors, leading to decreased levels of proinflammatory cytokines and attenuation of inflammation in TNBS-induced murine colitis. 32 
Atypical Cannabinoids
Little is known about the mechanistic pathways of atypical cannabinoids in murine colitis, but they seem to play a dynamic role in attenuation of inflammation. Atypical cannabinoid and GPR55 agonist O-1602 attenuates inflammation in both DSS-induced and TNBS-induced colitis in WT mice, and this effect is preserved when tested in CB 1 2/2 and CB 2 2/2 mice and in GPR55 2/2 mice, indicating that this therapeutic effect may have been achieved by off-target effect or by alternate pathways. 33 Conversely, GPR55 antagonist CID16020046 attenuated inflammation in DSS-induced colitis, and GPR55 2/2 mice showed reduced inflammation scores as compared with WT mice in the DSS model, both suggesting that GPR55 activates a proinflammatory signal in intestinal inflammation. 34 Atypical cannabinoid PEA, which has been shown to act through several targets, including CB 1 receptors, CB 2 receptors, TRPV1 channels, PPARs, and GPR55, was found to be increased 2.5-fold in DNBS-treated colonic tissue, and led to attenuation of inflammation in this murine model of colitis. 16 In addition, PEA counteracted DNBS-induced downregulation of GPR55 and TRPV1; however, GPR55 antagonist ML-191 and PPARa antagonist GW6471 reduced the anti-inflammatory effects of PEA, whereas TRPV1 channel antagonist capsazepine had a synergistic anti-inflammatory effect. 16 Treatment of LPS-activated peritoneal macrophages with nonpsychotropic cannabinoid cannabichromene (CBC), a transient receptor potential ankyrin-type 1 (TRPA1) agonist, weak MAGL inhibitor, and inhibitor of endocannabinoid activation, significantly increased OEA levels. 14,26 CBC treatment also reduced proinflammatory cytokines and nitric oxide production, and this anti-inflammatory effect was mimicked by cannabinoid receptor and TRPA1 agonists carvacrol and cinnamaldehyde, further enhanced by CB 1 receptor antagonists rimonabant and AM251, with no change on CBC effect by CB 2 antagonist SR144528. 14, 26 Finally, CBC treatment attenuated DNBS-induced colitis in ICR mice, although the exact mechanistic pathway of these effects is somewhat unknown. 14,26
MAGL and FAAH
As the enzymes responsible for degradation of endocannabinoids 2-AG and AEA, respectively, MAGL and FAAH are vital components in the ECS during the inflammatory cascade. A significant increase in FAAH activity was observed in croton oil-treated mice, 11 but in contrast, FAAH mRNA expression is significantly reduced in early stages of inflammation and returned to normal levels over time in multiple colitis models. 30, 35 In addition to the previously reviewed effects of a, b-amyrin as an anti-inflammatory agent through the CB 1 receptor pathway in DSS-induced colitis, preventive treatment with a,b-amyrin in DSS-induced colitis caused a marked decrease in both monoglyceride lipase 1 (MGL1) and FAAH mRNA expression, suggesting that the a,b-amyrin beneficial effects could be related to the modulation of endocannabinoid hydrolase expression. 13 In addition, MAGL and FAAH blockade are important in attenuation of colitis, and are closely linked to CB receptors in the ECS. Although FAAH inhibition was shown to ameliorate DSSinduced colitis in one study, 36 it failed to treat colitis using the same model in another study. 37 The FAAH inhibitor PF-3845 successfully attenuated TNBS-induced colitis. 37 Potent MAGL inhibitor JZL184 attenuated TNBS-induced murine colitis while preserving the expression of MAGL and altering function only. 32 The MAGL inhibitory pathway also involves the CB 1 and CB 2 receptors, as administration of the MAGL inhibitor JZL184 in the presence of CB 1 receptor antagonist SR141716A and CB 2 receptor antagonist AM630 completely abolished the protective effect of MAGL inhibition. 32 Furthermore, FAAH inhibitor URB597 attenuated TNBSinduced colitis, and this anti-inflammatory effect was abolished in both CB 1 2/2 and CB 2 2/2 mice. 35 Lastly, FAAH 2/2 mice are impaired in their ability to degrade AEA and display protection from DNBS-induced colitis as compared with the more severe inflammation seen in their FAAH +/+ littermates 12 (Table 2) .
Impact of Cannabinoids in Human Disease
Several studies have looked at the ECS and its effects on human immune cell function. AEA has been shown to suppress proliferation and cytokine release from human T-lymphocytes through the CB 2 receptor. 38 Also, human neutrophil transmigration in vitro is impaired by treatment with synthetic cannabinoid receptor agonist WIN 55,212-2, although the mechanism does not seem to be mediated through the CB 1 or CB 2 receptor, 39 suggesting an off-target effect may be responsible.
In addition, 2 plant cannabinoids, THC and CBD, have received greatest interest for their therapeutic potential in humans. THC, the partial CB 1/2 receptor agonist which was the first identified active ingredient in cannabis with potent psychotropic effects, 40 can suppress production of IFN-g by human CD4 + T cells in vitro albeit at relatively high concentrations. 41 THC has also been shown to enhance transforming growth factor (TGF)-b production 42 in unfractionated human peripheral blood mononuclear cells and reduces both cyclic adenosine monophosphate 43 and IL-10 production 44 by human lymphocytes through the CB 2 receptor.
CBD first gained interest when it was shown to provide significant improvement in a phase II placebo-controlled clinical trial for the treatment of epilepsy. 45 CBD has been reported to suppress TNF-a, IL-1b, and IFN-g production by human peripheral blood mononuclear cells. 46 In contrast to THC, CBD seems to have little or no CB 1 receptor or CB 2 receptor affinity, 47 and a number of possible alternative methods have been postulated for its mechanism of action, including prolonging of the effect of AEA. In a study looking at CBD in schizophrenia, CBD enhanced AEA signaling 48 potentially by acting as a false substrate for FAAH. CBD can also enhance adenosine signaling by inhibiting its uptake through equilibrative nucleoside transporter 1. 49 CBD, however, has also been reported to strongly inhibit IL-10 production by a human HUT-78 T cell line. 44 Interestingly, CBD increases TGF-b production 50 at low doses, which is important for expansion of both Treg and Th17 cells, but does the reverse at high CBD concentrations suggesting that there may be a significant dose effect in patients. Three observational studies focused on MJ use in adults with IBD report subjective improvement in symptoms with MJ use, [51] [52] [53] but the study by Storr et al in 2014 also demonstrated increased surgical procedures in those with use of MJ for greater than 6 months. 53 A prospective trial using THC versus placebo for the treatment of Crohn's disease in 21 patients found statistically significant reductions in Crohn's Disease Activity Index scores and increased quality of life in the THC treatment group; however, there was no change in serum markers of inflammation in either the THC treatment or the placebo group. 6 Lastly, a clinical trial sponsored by Bial and performed by Biotrial studied the effect of a FAAH inhibitor as an analgesic in human subjects, but the study was aborted after 5 of the 6 subjects developed significant neurologic side effects, including one death. 54 Subsequent investigations coupled with studies on other FAAH inhibitors strongly suggest that this is highly unlikely to represent a class effect.
DISCUSSION
The ECS and its components, including CB 1 and CB 2 receptors, endocannabinoids AEA and 2-AG, atypical cannabinoids, and endocannabinoid hydrolases FAAH and MAGL, are vastly interrelated but incompletely understood pathways that highly contribute to attenuation of murine colitis. Plant cannabinoids THC and CBD proved beneficial in DNBS-induced colitis in a bell-shaped dose-related response, but more importantly, the effects of the phytocannabinoids were additive, as CBD increased an ineffective THC dose to the level of an effective one. 55 As previously discussed, TNBS induced a more severe colitis in CB 1 2/2 mice, CB 2 2/2 mice, and in CB 1/2 double knockout mice as compared with WT littermates; however, there was no difference in the severity of colitis between CB 1 2/2 , CB 2 2/2 , or the CB 1/2 double knockout mice, indicating the importance of the presence of both cannabinoid receptor pathways in the attenuation of inflammation. 19 Moreover, covalent cannabinoid agonist AM841 attenuated both DSS-induced and TNBS-induced colitis when administered both before induction of colitis as well as a treatment for existing inflammation, and this anti-inflammatory effect was abolished in the setting of CB 1 2/2 mice, CB 2 2/2 mice, as well as in CB 1/2 double knockout mice, which provides further evidence to support the vital role of both cannabinoid pathways in attenuation of murine colitis. 56 Finally, MAGL and FAAH blockade, as well as blockade of atypical cannabinoid receptor TRPV1, 57 are important in attenuation of colitis, and studies demonstrate a close link of these endocannabinoid hydrolases to CB receptors in the ECS (Fig. 2) .
Investigators have produced similar results from manipulation of the ECS in other disease models of inflammation. In the FIGURE 2. Therapeutic targeting of the ECS in murine colitis. A schematic overview of cannabinoid receptors, the endogenous cannabinoids that act on them, pathway of enzymatic degradation of endocannabinoids, and how manipulation of this pathway impacts colitis. mixed lymphocyte reaction (MLR), an in vitro correlate of organ graft rejection, selective CB 2 agonists JWH-015 and O-1966, as well as THC, significantly suppressed the MLR (thus inflammation) in a dose-dependent fashion, and this effect was reversed in the setting of CB 2 antagonist SR144528 but not in the presence of CB 1 antagonist SR141716A, 58 indicating that the anti-inflammatory effect was CB 2 receptor mediated. In the same MLR model, selective CB 2 agonist O-1966 increased the percentage of T regulatory cells (Treg), decreased active markers of inflammation including transcription factors on T cells, and decreased proinflammatory cytokines, but these anti-inflammatory effects were abolished in CB 2 2/2 mice, and the increased Treg percentage was reversed with the administration of anti-IL-10. 59 In Theiler's virus (TMEV)-activated macrophages, a viral model of multiple sclerosis, CB 2 agonist JWH-133, inhibited inflammation and this effect was reversed in the presence of CB 2 antagonist SR144528. 24 Thus, the mammalian ECS likely plays an important role in a multitude of inflammatory diseases, and with time, novel drug therapies targeting the ECS may prove critical for the advancement of therapeutics in inflammatory disease, including IBD.
Multiple studies have struggled to elucidate specific mechanistic pathways in attenuation of inflammation, but nonetheless, their findings highlight the importance of manipulation of the ECS to produce biological effects. Two groups investigated intraperitoneal administration of peripherally restricted CB agonists and found that they had no effect on murine colitis, suggesting an inclusive role of central nervous system receptors. 17, 56 One group went a step further and demonstrated that intracerebroventricular (i.c.v.) administration of peripherally restricted CB agonists attenuated colitis, imparting credibility to the concept that both central and peripheral CB receptors are responsible for the protective and therapeutic effects of cannabinoids, 56 and that the lack of efficacy in peripheral restriction could be overcome by systemic administration.
Furthermore, upregulation in expression of the components of the ECS in the setting of murine colitis may be location and timing dependent. In one study, there was marked upregulation of CB 2 expression in the proximal colon within one day of TNBS instillation which progressed to the distal colon by day 3, consistent with the aboral direction of disease progression; these findings were mirrored in the DSS-induced colitis model as well. 22 An additional study notes that the method of administration may be critical in attenuating inflammation, as intraperitoneal (i.p.) and rectal administration of CBD attenuated TNBS-induced colitis but oral administration made no effect on inflammation. 60 These studies highlight the complicated nature of the ECS, and suggest that further research to clearly elucidate the specific mechanistic pathways of the ECS will be crucial to the development of therapeutics to target inflammation.
CONCLUSION
There is a significant need for the development of highly novel therapies for the treatment of IBD, as IBD is one of the most prevalent and costly GI disorders whose annual incidence and prevalence is on the rise. Manipulation of multiple pathways of the ECS in murine colitis has proven to be beneficial in attenuating inflammation, and the ECS pathway may offer an innovative approach to enhance the impaired host regulatory system in patients with IBD. However, studies on the impact of manipulation of the ECS in intestinal inflammation are lacking, as the few human trials on MJ use in IBD have evaluated subjective, although positive, results only and failed to evaluate objective histologic data. This review highlights the complicated nature of the ECS, its critical role in a multitude of inflammatory diseases, and emphasizes that further research to clearly elucidate the specific mechanistic pathways of the ECS is essential to the development of therapeutics to target inflammation.
